Cargando…
Factors Influencing the Efficacy of Umbilical Cord Blood-Derived Cell Therapy for Perinatal Brain Injury
INTRODUCTION: We have previously described preclinical literature which supports umbilical cord blood-derived cell (UCBC) therapy as an efficacious treatment for perinatal brain injury. However, efficacy of UCBCs may be influenced by different patient population and intervention characteristics. OBJ...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10021495/ https://www.ncbi.nlm.nih.gov/pubmed/36847059 http://dx.doi.org/10.1093/stcltm/szad006 |
_version_ | 1784908500552384512 |
---|---|
author | Purcell, Elisha Nguyen, Timothy Smith, Madeleine Penny, Tayla Paton, Madison C B Zhou, Lindsay Jenkin, Graham Miller, Suzanne L McDonald, Courtney A Malhotra, Atul |
author_facet | Purcell, Elisha Nguyen, Timothy Smith, Madeleine Penny, Tayla Paton, Madison C B Zhou, Lindsay Jenkin, Graham Miller, Suzanne L McDonald, Courtney A Malhotra, Atul |
author_sort | Purcell, Elisha |
collection | PubMed |
description | INTRODUCTION: We have previously described preclinical literature which supports umbilical cord blood-derived cell (UCBC) therapy as an efficacious treatment for perinatal brain injury. However, efficacy of UCBCs may be influenced by different patient population and intervention characteristics. OBJECTIVES: To systematically review the effects of UCBCs on brain outcomes in animal models of perinatal brain injury across subgroups to better understand the contribution of model type (preterm versus term), brain injury type, UCB cell type, route of administration, timing of intervention, cell dosage, and number of doses. METHODS: A systematic search of MEDLINE and Embase databases was performed to identify studies using UCBC therapy in animal models of perinatal brain injury. Subgroup differences were measured by chi(2) test where possible. RESULTS: Differential benefits of UCBCs were seen across a number of subgroup analyses including intraventricular hemorrhage (IVH) vs. hypoxia ischemia (HI) model (apoptosis white matter (WM): chi(2) = 4.07; P = .04, neuroinflammation-TNF-α: chi(2) = 5.99; P = .01), UCB-derived mesenchymal stromal cells (MSCs) vs. UCB-derived mononuclear cells (MNCs) (oligodendrocyte WM: chi(2) = 5.01; P = .03, neuroinflammation-TNF-α: chi(2) = 3.93; P = .05, apoptosis grey matter (GM), astrogliosis WM), and intraventricular/intrathecal vs. systemic routes of administration (microglial activation GM: chi(2) = 7.51; P = .02, astrogliosis WM: chi(2) = 12.44; P = .002). We identified a serious risk of bias and overall low certainty of evidence. CONCLUSIONS: Preclinical evidence suggests UCBCs to show greater efficacy in the injury model of IVH compared to HI, the use of UCB-MSCs compared to UCB-MNCs and the use of local administrative routes compared to systemic routes in animal models of perinatal brain injury. Further research is needed to improve certainty of evidence and address knowledge gaps. |
format | Online Article Text |
id | pubmed-10021495 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-100214952023-03-18 Factors Influencing the Efficacy of Umbilical Cord Blood-Derived Cell Therapy for Perinatal Brain Injury Purcell, Elisha Nguyen, Timothy Smith, Madeleine Penny, Tayla Paton, Madison C B Zhou, Lindsay Jenkin, Graham Miller, Suzanne L McDonald, Courtney A Malhotra, Atul Stem Cells Transl Med Concise Reviews INTRODUCTION: We have previously described preclinical literature which supports umbilical cord blood-derived cell (UCBC) therapy as an efficacious treatment for perinatal brain injury. However, efficacy of UCBCs may be influenced by different patient population and intervention characteristics. OBJECTIVES: To systematically review the effects of UCBCs on brain outcomes in animal models of perinatal brain injury across subgroups to better understand the contribution of model type (preterm versus term), brain injury type, UCB cell type, route of administration, timing of intervention, cell dosage, and number of doses. METHODS: A systematic search of MEDLINE and Embase databases was performed to identify studies using UCBC therapy in animal models of perinatal brain injury. Subgroup differences were measured by chi(2) test where possible. RESULTS: Differential benefits of UCBCs were seen across a number of subgroup analyses including intraventricular hemorrhage (IVH) vs. hypoxia ischemia (HI) model (apoptosis white matter (WM): chi(2) = 4.07; P = .04, neuroinflammation-TNF-α: chi(2) = 5.99; P = .01), UCB-derived mesenchymal stromal cells (MSCs) vs. UCB-derived mononuclear cells (MNCs) (oligodendrocyte WM: chi(2) = 5.01; P = .03, neuroinflammation-TNF-α: chi(2) = 3.93; P = .05, apoptosis grey matter (GM), astrogliosis WM), and intraventricular/intrathecal vs. systemic routes of administration (microglial activation GM: chi(2) = 7.51; P = .02, astrogliosis WM: chi(2) = 12.44; P = .002). We identified a serious risk of bias and overall low certainty of evidence. CONCLUSIONS: Preclinical evidence suggests UCBCs to show greater efficacy in the injury model of IVH compared to HI, the use of UCB-MSCs compared to UCB-MNCs and the use of local administrative routes compared to systemic routes in animal models of perinatal brain injury. Further research is needed to improve certainty of evidence and address knowledge gaps. Oxford University Press 2023-02-27 /pmc/articles/PMC10021495/ /pubmed/36847059 http://dx.doi.org/10.1093/stcltm/szad006 Text en © The Author(s) 2023. Published by Oxford University Press. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com. |
spellingShingle | Concise Reviews Purcell, Elisha Nguyen, Timothy Smith, Madeleine Penny, Tayla Paton, Madison C B Zhou, Lindsay Jenkin, Graham Miller, Suzanne L McDonald, Courtney A Malhotra, Atul Factors Influencing the Efficacy of Umbilical Cord Blood-Derived Cell Therapy for Perinatal Brain Injury |
title | Factors Influencing the Efficacy of Umbilical Cord Blood-Derived Cell Therapy for Perinatal Brain Injury |
title_full | Factors Influencing the Efficacy of Umbilical Cord Blood-Derived Cell Therapy for Perinatal Brain Injury |
title_fullStr | Factors Influencing the Efficacy of Umbilical Cord Blood-Derived Cell Therapy for Perinatal Brain Injury |
title_full_unstemmed | Factors Influencing the Efficacy of Umbilical Cord Blood-Derived Cell Therapy for Perinatal Brain Injury |
title_short | Factors Influencing the Efficacy of Umbilical Cord Blood-Derived Cell Therapy for Perinatal Brain Injury |
title_sort | factors influencing the efficacy of umbilical cord blood-derived cell therapy for perinatal brain injury |
topic | Concise Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10021495/ https://www.ncbi.nlm.nih.gov/pubmed/36847059 http://dx.doi.org/10.1093/stcltm/szad006 |
work_keys_str_mv | AT purcellelisha factorsinfluencingtheefficacyofumbilicalcordbloodderivedcelltherapyforperinatalbraininjury AT nguyentimothy factorsinfluencingtheefficacyofumbilicalcordbloodderivedcelltherapyforperinatalbraininjury AT smithmadeleine factorsinfluencingtheefficacyofumbilicalcordbloodderivedcelltherapyforperinatalbraininjury AT pennytayla factorsinfluencingtheefficacyofumbilicalcordbloodderivedcelltherapyforperinatalbraininjury AT patonmadisoncb factorsinfluencingtheefficacyofumbilicalcordbloodderivedcelltherapyforperinatalbraininjury AT zhoulindsay factorsinfluencingtheefficacyofumbilicalcordbloodderivedcelltherapyforperinatalbraininjury AT jenkingraham factorsinfluencingtheefficacyofumbilicalcordbloodderivedcelltherapyforperinatalbraininjury AT millersuzannel factorsinfluencingtheefficacyofumbilicalcordbloodderivedcelltherapyforperinatalbraininjury AT mcdonaldcourtneya factorsinfluencingtheefficacyofumbilicalcordbloodderivedcelltherapyforperinatalbraininjury AT malhotraatul factorsinfluencingtheefficacyofumbilicalcordbloodderivedcelltherapyforperinatalbraininjury |